Table 2.
Univariate and multivariate analyses of overall survival in patients with resected pancreatic cancer (N = 200)
| Clinical variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age > 70 | 1.12 | 0.75-1.66 | 0.56 | |||
| Gender (male) | 1.43 | 0.96-2.14 | 0.08 | |||
| CEA (> 3.4 ng/mL) | 1.54 | 1.01-2.32 | 0.046 | NS | ||
| CA19-9 (> 37 U/L) | 2.29 | 1.48-3.67 | 0.001 | NS | ||
| Blood loss (> 550 g) | 1.51 | 1.04-2.20 | 0.028 | NS | ||
| Operation time (> 700 min) | 1.14 | 0.79-1.65 | 0.47 | |||
| T stage (T3, T4) | 1.99 | 1.17-3.22 | 0.013 | 2.55 | 1.30-5.39 | 0.002 |
| Lymph node positive | 2.23 | 1.54-3.60 | < 0.001 | 1.16 | 1.07-2.53 | 0.009 |
| Morbidity (CDCs > III) | 1.27 | 0.84-2.01 | 0.25 | |||
| Adjuvant chemotherapy | 0.75 | 0.45-1.30 | 0.29 | |||
| Statin intake | 0.61 | 0.37-0.96 | 0.024 | 0.59 | 0.35-0.93 | 0.021 |
NS, not significant; HR, hazard ratio; CDCs, Clavien-Dindo classification. The T stage was used by the UICC for International Cancer Control 7th edition.